Integrating high-fidelity hiPSC-cardiomyocytes with AI-driven modeling for enhanced proarrhythmic risk assessment

Su-Bin Kim1, Jaehun Lee1, Jieun An1

  • 1Department of Commercializing iPSC Technology, NEXEL Co., Ltd., 8th floor, 55 Magokdong-Ro, Gangseo-Gu, Seoul, 07802, Republic of Korea.

Archives of Toxicology
|April 28, 2026
PubMed

Insights

This study introduces an AI-powered platform using human stem cell-derived cardiomyocytes to accurately predict drug-induced heart risks. The system effectively identifies cardiotoxicity missed by traditional assays, improving drug safety screening.

Area of Science:

  • Cardiovascular toxicology
  • Stem cell biology
  • Artificial intelligence in drug discovery

Background:

  • Drug-induced cardiotoxicity is a major cause of drug failure, with current prediction methods being suboptimal.
  • Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) offer a human-relevant model aligning with regulatory guidelines (CiPA, ICH E14/S7B).

Purpose of the Study:

  • To validate an integrated platform combining hiPSC-CMs and AI for enhanced prediction of drug-induced proarrhythmic risk.
  • To assess the platform's ability to detect functional cardiotoxicity often missed by standard assays.

Main Methods:

  • Phenotypic characterization of hiPSC-CMs for cardiac differentiation efficiency and cell identity.
  • Electrophysiological data collection from 28 CiPA reference compounds using Multielectrode Array (MEA).
  • Training and evaluation of machine learning models, including Artificial Neural Networks, for risk prediction.

Main Results:

  • The AI-hiPSC-CM platform achieved a high predictive accuracy (ROC-AUC of 0.982) using an Artificial Neural Network.
  • The platform identified functional cardiotoxicity (FPDcF prolongation) in anticancer agents (sunitinib, erlotinib) that lacked overt structural cytotoxicity.
  • These agents were classified as high-to-intermediate risk for Torsades de Pointes (TdP), quantifying time-dependent liabilities.

Conclusions:

  • The validated AI-hiPSC-CM platform accurately detects hidden functional cardiotoxicity, improving upon traditional methods.
  • This integrated system serves as a high-throughput, early-stage safety screening tool, bridging in vitro findings with clinical outcomes.
  • The platform provides a standardized framework for assessing drug-induced proarrhythmic risk, enhancing drug development safety.

Related Concept Videos